Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 1999, p. 1383-1386, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Trailing End Point Phenotype in Antifungal
Susceptibility Testing Is pH Dependent
Kieren A.
Marr,1,2,*
Tige R.
Rustad,3
John H.
Rex,4 and
Theodore C.
White3,5
Fred Hutchinson Cancer Research
Center,1 Departments of
Medicine2 and
Pathobiology,3 University of Washington,
and Seattle Biomedical Research
Institute,5 Seattle, Washington, and
Division of Infectious Diseases, Department of Internal
Medicine, Center for the Study of Emerging and Reemerging
Pathogens, University of Texas Medical School, Houston,
Texas4
Received 21 January 1999/Returned for modification 3 March
1999/Accepted 18 March 1999
 |
ABSTRACT |
The interpretation of end points in azole antifungal drug
susceptibility testing is problematic, in part due to incomplete growth
inhibition of Candida species. Such trailing growth can cause the MICs of fluconazole for some isolates to be low (<1 µg/ml)
after 24 h of growth but much higher (>64 µg/ml) after 48 h. Isolates having this type of growth have been described as having a
low-high phenotype. Although these isolates would be considered
resistant by current National Committee of Clinical Laboratory
Standards definitions, growing evidence suggests that they are
susceptible in vivo. To further characterize these isolates in vitro,
microdilution susceptibility testing comparing the complex defined
medium RPMI 1640 to a defined minimal medium (yeast nitrogen broth) was
performed. Isolates having trailing growth in MOPS (morpholinepropanesulfonic acid)-buffered RPMI 1640 (pH 7.0) were found
to have clear end points in the minimal medium at its native pH of 4.5. The pH of the medium influenced the low-high phenotype, as these same
isolates trailed in minimal medium adjusted to a pH of
6.0 but did
not trail in RPMI 1640 adjusted to a pH of
5.0. This pH effect was
independent of the medium buffering capacity, as trailing was decreased
in both minimal medium and RPMI 1640 (pH 4.5) buffered in citrate.
Adjustment in the pH of MOPS-buffered RPMI 1640 reduced trailing in
multiple strains of Candida albicans without affecting the
MICs for isolates having known susceptible (low-low) and resistant
(high-high) phenotypes. Adjustment of the medium pH could be considered
to eliminate trailing in azole drug susceptibility testing.
 |
INTRODUCTION |
Antifungal drug resistance has
become increasingly important as yeasts have become a leading cause of
nosocomial bloodstream infection in the United States (7).
The development of a standardized method for antifungal susceptibility
testing of yeasts by the National Committee for Clinical Laboratory
Standards (NCCLS) (5) was a major advance which has
facilitated both the development of interpretive breakpoints for in
vivo resistance and epidemiological and molecular studies of drug
resistance (11, 12, 16).
The approved-level version of the NCCLS document for antifungal
susceptibility testing, document M27-A, includes broth macrodilution and microdilution methods for the determination of azole
susceptibility. Although these methods have been found to be
reproducible in many laboratories, the optimal end point turbidity and
duration of incubation have yet to be established (10).
Concern has arisen over the phenomenon of trailing growth in serial
dilution testing, in which reduced but persistent growth of
Candida species in high concentrations of an azole
antifungal agent confuses end point determination. The NCCLS M27-A
document addresses this problem by defining resistant isolates as those
not achieving an 80% reduction in growth relative to the growth
control in macrodilution testing and those not achieving a "prominent
reduction in turbidity" in microdilution testing after 48 h in
the presence of specified high concentrations of azole antifungal
agents (5). For some isolates, however, trailing growth is
so significant that the MICs for these isolates will appear to be low
after 24 h but much higher after 48 h. For example, in the
case of fluconazole, isolates for which the MICs are <4 µg/ml at
24 h and >64 µg/ml at 48 h have been described
(10). These MICs are so discordant that they place the
isolate into different MIC interpretive categories at the two time
points, and we refer the isolates as having a low-high MIC phenotype.
While the true relevance of such discordant MICs is as yet unclear,
current evidence suggests that the lower MIC correlates most closely
with the outcome in vivo. Isolates with the low-high phenotype obtained
from the mouths of HIV-infected patients with oropharyngeal candidiasis
appeared to respond clinically to fluconazole administration in the
same fashion as susceptible yeasts (8). In another study,
mice were infected with susceptible, resistant, and low-high-phenotype
isolates. The low-high-phenotype isolates responded to fluconazole
therapy in the same manner as the susceptible isolates, despite the
fact that the NCCLS M27-A MIC of fluconazole for those isolates was
>64 µg/ml (10).
The cause(s) of trailing growth has not been determined. Previous
studies have documented that inoculum size, incubation time, medium pH,
and buffer concentration can significantly alter susceptibility results, but studies have not specifically addressed trailing growth
(14). In this study, we examined the effects of different media on the trailing behavior of clinical isolates that have been
found to trail in vitro but that act as susceptible isolates in an
animal model (10).
 |
MATERIALS AND METHODS |
Strains and media.
The strains used in this study are listed
in Table 1. All are clinical isolates,
from both patients with oropharyngeal candidiasis and patients with
candidemia (10). Many of the isolates were previously used
in a study examining the low-high phenotype in an animal model
(10). The isolates were stored at
70°C and subcultured
on yeast extract peptone dextrose agar (10 g of yeast extract, 20 g of peptone, 20 g of glucose, 20 g of agar per liter) prior
to antifungal susceptibility testing. All isolates had previously undergone fluconazole susceptibility testing by the M27-A microdilution procedure and were classified as having a low-low, high-high, or
low-high fluconazole MIC phenotype, according to the definitions described below.
Susceptibility testing was performed in RPMI 1640 (supplemented with
glutamine [American Bioorganics, Niagara Falls, N.Y.]) and yeast
nitrogen base with ammonium and dextrose (YAD; 1.7 g of yeast
nitrogen base without ammonium sulfate or amino acids, 5 g of
ammonium sulfate, 5.4 g of dextrose per liter). RPMI 1640 and YAD
were adjusted to pH values ranging from 4.0 to 7.0, using NaOH or HCl.
As noted in the text, buffering was achieved with morpholinepropanesulfonic acid (MOPS; 0.165 M) and, in specific experiments, with 10 mM citrate (Sigma, St. Louis, Mo.).
Susceptibility testing and definitions.
Fluconazole powder
of known potency was obtained from Pfizer (New York City, N.Y.).
Susceptibility to fluconazole was tested by the NCCLS broth
macrodilution and microdilution methods (5). In
microdilution testing, growth was measured with an automated microtiter
reader (EIA Autoreader, Bio-Tek Instruments) at a wavelength of 530 nm
after 24 and 48 h of growth. The optical density of the drug- and
fungus-free control well was subtracted from all test readings, and the
ratio of growth with the drug to growth without the drug was computed
at each drug concentration. The MIC was computed as the lowest
concentration of fluconazole to cause an 80% inhibition of growth
relative to that of the drug-free control (MIC80).
Isolates for which the fluconazole MICs at 24 and 48 h were
16
µg/ml were defined as having a low-low phenotype. Isolates for which
the MICs at 24 and 48 h were >8 and
32 µg/ml, respectively, were defined as having a high-high phenotype. Isolates for which the
24-h MIC was
8 µg/ml and the 48-h MIC was
32 µg/ml were defined
as having the low-high phenotype. This low-high phenotype thus most
accurately describes isolates that have trailing end points, or
discordant MIC interpretations, after 24 and 48 h of growth.
 |
RESULTS |
Susceptibility behavior was tested for the trailing isolate 707-15 in MOPS-buffered RPMI 1640 at pH 7.0 and in YAD lacking supplemental
buffer unbuffered at pH 4.5. Isolate 707-15 was previously tested in an
animal model and found to respond as a susceptible isolate
(10). As is seen in Fig. 1,
this isolate has a low-high phenotype in MOPS-buffered RPMI 1640 but it
has a low-low phenotype in unbuffered YAD.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of medium on trailing. The susceptibility of
isolate 707-15 to fluconazole was tested in RPMI 1640 (solid symbols)
and YAD (open symbols), using the microtiter version of the M27-A
method, as described in the text. Relative growth (y axis)
is calculated as the percentage of growth (optical density at 530 nm)
relative to growth in a drug-free well (Growth Control) for serial
dilutions of fluconazole (x axis). The squares represent
48-h readings, and the circles represent 24-h readings of the same
plate. The results represent the means from experiments performed in
triplicate.
|
|
To determine if a different pH was the cause of the change in
phenotype, the susceptibility behavior of the Candida
albicans isolate (707-15) was determined in MOPS-buffered RPMI
1640 adjusted to a pH of 4.0 and in unbuffered YAD adjusted to a pH of
7.0 (Fig. 2). The low-low phenotype was
seen in both MOPS-buffered RPMI 1640 and unbuffered YAD with a pH of
4.0, and the low-high phenotype occurred in both media at a pH of 7.0. The effect of the medium pH was further explored by performing
susceptibility measurements in MOPS-buffered RPMI 1640 and unbuffered
YAD at a range of pH values (Fig. 3). Figure
3 shows the behavior of the trailing
isolate 707-15 in the two different medium pH arrays. In these studies, isolate 707-15 clearly has less inhibition of growth after 48 h in
medium having a high pH. The low-high phenotype was observed at a pH of
5.0 in RPMI 1640 (Fig. 3A) and
5.5 in YAD (Fig. 3B).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of medium pH on trailing. C. albicans
isolate 707-15 was grown for 48 h in MOPS-buffered RPMI 1640 (solid symbols) and unbuffered YAD (open symbols), as described in the
text. Relative growth (y axis) is calculated as the
percentage of growth (optical density at 530 nm) relative to growth in
a drug-free well (Growth Control) for serial dilutions of fluconazole
(x axis). Significant trailing was seen with both media
adjusted to a pH of 7.0 (squares) but not in media adjusted to a pH of
4.0 (circles).
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
pH arrays in RPMI 1640 and YAD. C. albicans
trailing isolate 707-15 was used to assess trailing in RPMI 1640 (A)
and YAD (B) adjusted to pHs 7 (solid squares), 6.5 (solid diamonds),
6.0 (solid triangles), 5.5 (solid circles), 5.0 (open triangles), 4.5 (open squares), and 4.0 (open diamonds). All media were buffered in
MOPS (0.165 M) and incubated with shaking at 33°C. Relative growth
(y axis) is calculated as the percentage of growth (optical
density at 530 nm) relative to growth in a drug-free well (Growth
Control), for serial dilutions of fluconazole (x axis).
Shown are the results of growth after 48 h.
|
|
The susceptibility to fluconazole was determined for multiple C. albicans and non-albicans Candida species, using both
unbuffered YAD at its native pH of 4.5 and MOPS-buffered RPMI 1640 at
pH 7.0 (Table 1). The low-high phenotype of all C. albicans
and Candida tropicalis isolates was eliminated in unbuffered
YAD at a pH of 4.5. The fluconazole MICs determined in the two media were similar for most isolates, with the exceptions shown.
Since the elimination of trailing was observed in media that lacked
supplemental buffer and with a low pKa, it was possible that the change in trailing behavior merely reflected a lack of buffering capacity in the medium. A decrease in medium pH after 24 h of growth in unbuffered medium might have been the cause of the
subsequent growth inhibition. This hypothesis was tested by buffering
YAD and RPMI 1640 with 10 mM citrate, a buffer with a pKa
of 4.77, and adjusting the pHs of both media to 4.5. The behavior of
the isolate did not change relative to that in medium lacking citrate
buffer. In MOPS-buffered RPMI 1640 at pH 4.5, the MIC for 707-15 after
48 h of growth was 1.0 (Fig. 3A), and in citrate-buffered RPMI
1640 at pH 4.5, the MIC was 2 (data not shown). The 48-h MIC for 707-15 was 4.0 in both MOPS-buffered YAD at pH 4.5 (Fig. 3B) and YAD buffered
with citrate at pH 4.5 (data not shown). As was noted in Fig. 3, the
48-h MICs for the same isolate in both media at a pH of 7.0 was greater
than 64 µg/ml. Thus, the inhibition of trailing growth in media
having low pH is consistent and independent of buffer and buffering capacity.
Susceptibility testing was repeated for the low-high-phenotype isolate
(707-15) by the macrodilution method. Growth inhibition was clearly
much more visible "by the naked eye" when the testing was performed
in citrate-buffered RPMI 1640 (pH 4.5) than when it was performed in
MOPS-buffered RPMI 1640 (pH 7.0), and the end points were consistent
with those found by the microdilution method (data not shown).
 |
DISCUSSION |
Although the development of a standardized method for
antifungal susceptibility testing and the establishment of
breakpoints for fluconazole susceptibility mark major advances in the
field of medical mycology, the complexities of susceptibility testing are numerous and optimization of the methodology is ongoing. Although the standardized NCCLS method has been found to have good
interlaboratory reproducibility, many of the variables (time, medium,
and end point) were adopted arbitrarily (9). The trailing
phenomenon demonstrates an in vitro-in vivo discrepancy that might be
eliminated by subtle alterations in the susceptibility-testing
protocol. Previous authors have verified that isolates having a
low-high phenotype are susceptible in vivo despite the fact that the
48-h fluconazole MIC for these isolates is >64 µg/ml. Revankar et
al. found that episodes of oropharyngeal candidiasis caused by such C. albicans isolates in patients with HIV infection respond
to low doses (100 mg/day) of fluconazole (8). In a mouse
model, low-high-phenotype C. albicans isolates respond to
fluconazole administration in a manner that is equivalent to those
having a low-low MIC phenotype (10). In this study, these
same isolates were found to have clear susceptible MIC end points when
testing was performed in the minimal medium YAD. Further experiments
showed that the critical factor changing this behavior is medium pH. This observation not only has potential importance in the
interpretation and development of antifungal susceptibility testing, it
also yields important information pertaining to azole susceptibility mechanisms and Candida physiology.
The complexity of antifungal susceptibility testing is illustrated by
the observations that inoculum size, incubation time, temperature,
presence of shaking, and choice of medium can alter susceptibility
results (1, 9). Previous studies have found that the medium
pH can alter the azole MICs for Candida species. An acidic
pH has been noted to increase the MICs of fluconazole for selected
Candida species in several studies (3, 6, 13). In
this study, few isolates had a minimal (twofold) increase in MIC under
acidic conditions, but these findings did not change the classification
of the isolates from susceptible to resistant. Of interest is the fact
that this observation appears to be repeated in specific
Candida species. For instance, several isolates of Candida lusitaniae behaved in this manner in this study and
in that by Peng and Galgiani (6). The slight increase in MIC
in YAD may be the result of the difference in medium composition. In
contrast, other isolates in this study were found to have increased MICs in RPMI 1640 compared to those in YAD, which appeared to be
unrelated to the trailing effect (Table 1). Whether these isolates are
in fact susceptible or resistant to fluconazole in vivo, or why there
appears to be a difference between Candida species, is as
yet unknown.
The results of these experiments suggest that acidic conditions
decrease the trailing effect in all isolates, independent of the medium
tested or the buffering capacity. Multiple previous studies have found
that high concentrations of buffer (MOPS) result in increased MICs
(2, 14, 15). These findings are consistent with our study in
that low concentrations of buffer may result in changes in pH during
incubation, thus decreasing the trailing effect at a 48-h MIC reading.
Although buffered medium at a pH of 7.0 has been accepted as standard,
it is not yet clear that this pH is optimal with regard to clinical
relevance. McIntyre and Galgiani previously found that cilofungin MICs
were highly variable in medium having a pH of 7.0 and much less varied
when tested at a pH of 3. Animal studies subsequently suggested that
the lower pH more accurately predicted the clinical outcome
(4). The finding that trailing can be decreased under acidic
conditions supports this concept for fluconazole as well, although more
studies are necessary to document whether isolates with differing MICs
are in fact susceptible or resistant in vivo. Also, it should be noted
that this study does not address the effect of acidic medium pH on the
susceptibility testing of other antifungal drugs. Further studies are
necessary in order to determine if modifications (changes in medium or
duration of incubation) should be made in our current antifungal
susceptibility testing methods.
The mechanism by which pH affects trailing has not yet been determined.
Since the isolates appeared to grow equally well in the absence of
fluconazole in RPMI 1640 at pH 4.0 to 7.0 (data not shown), the
explanation likely involves more than an alteration of the optical
density of the growth control. Other possible explanations include a pH
effect on cellular morphology and changes in the expression of genes
involved in drug resistance. It is possible that fluconazole has a more
"cidal" action at a low pH, as has been noted with the azole D0870
against Cryptococcus neoformans (17). Further
investigations to determine the mechanism of this observation are being performed.
 |
ACKNOWLEDGMENTS |
This research was supported in part by NIH Adult Leukemia
Research Center Core Grant CA18029 22 (Fred Hutchinson Cancer Research Center) and in part by NIH R01 DE11367 to T.C.W. K.A.M. is the recipient of the 1998 National Foundation of Infectious Diseases John
P. Utz Medical Mycology Fellowship. T.C.W. is supported by a New
Investigator Award from the M. J. Murdock Charitable Trust and is
the recipient of a New Investigator Award from the Burroughs Wellcome Fund.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Fred Hutchinson
Cancer Research Center, 1100 Fairview Ave. N. D3-100, Seattle, WA
98109-1024. Phone: (206) 667-2995. Fax: (206) 667-4411. E-mail:
Kmarr{at}u.washington.edu.
 |
REFERENCES |
| 1.
|
Anaissie, E.,
V. Paetznick, and G. P. Bodey.
1991.
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.
Antimicrob. Agents Chemother.
35:1641-1646[Abstract/Free Full Text].
|
| 2.
|
Hacek, D. M.,
G. A. Noskin,
K. Trakas, and L. R. Peterson.
1995.
Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory.
J. Clin. Microbiol.
33:1884-1889[Abstract].
|
| 3.
|
McIntyre, K. A., and J. N. Galgiani.
1989.
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 3904: effects of test conditions and relation to in vivo efficacy.
Antimicrob. Agents Chemother.
33:1095-1100[Abstract/Free Full Text].
|
| 4.
|
McIntyre, K. A., and J. N. Galgiani.
1989.
pH and other effects on the antifungal activity of cilofungin (LY 121019).
Antimicrob. Agents Chemother.
33:731-735[Abstract/Free Full Text].
|
| 5.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 6.
|
Peng, T., and J. N. Galgiani.
1993.
In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
Antimicrob. Agents Chemother.
37:2126-2131[Abstract/Free Full Text].
|
| 7.
|
Pfaller, M. A.,
R. N. Jones,
G. V. Doern,
H. S. Sader,
R. J. Hollis, and S. A. Messer.
1998.
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program.
J. Clin. Microbiol.
36:1886-1889[Abstract/Free Full Text].
|
| 8.
|
Revankar, S. G.,
W. R. Kirkpatrick,
R. K. McAtee,
A. W. Fothergill,
S. W. Redding,
M. G. Rinaldi, and T. F. Patterson.
1998.
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.
J. Clin. Microbiol.
36:153-156[Abstract/Free Full Text].
|
| 9.
|
Rex, J. H.,
M. A. Pfaller,
M. G. Rinaldi,
A. Polak, and J. N. Galgiani.
1993.
Antifungal susceptibility testing.
Clin. Microbiol. Rev.
6:367-381[Abstract/Free Full Text].
|
| 10.
|
Rex, J. H.,
P. W. Nelson,
V. L. Paetznick,
M. Lozano-Chiu,
A. Espinel-Ingroff, and E. J. Anaissie.
1998.
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.
Antimicrob. Agents Chemother.
42:129-134[Abstract/Free Full Text].
|
| 11.
|
Rex, J. H.,
M. A. Pfaller,
J. N. Galgiani,
M. S. Bartlett,
A. Espinel-Ingroff,
M. A. Ghannoum,
M. Lancaster,
F. C. Odds,
M. G. Rinaldi,
T. J. Walsh, and A. L. Barry.
1997.
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro/in vivo correlation data for fluconazole, itraconazole, and Candida infections.
Clin. Infect. Dis.
24:235-247[Medline].
|
| 12.
|
Rex, J. H.,
M. G. Rinaldi, and M. A. Pfaller.
1995.
Resistance of Candida species to fluconazole.
Antimicrob. Agents Chemother.
39:1-8[Medline].
|
| 13.
|
Rogers, T. E., and J. N. Galgiani.
1986.
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.
Antimicrob. Agents Chemother.
30:418-422[Abstract/Free Full Text].
|
| 14.
|
Tornatore, M. A.,
G. A. Noskin,
D. M. Hacek,
A. A. Obias, and L. R. Peterson.
1997.
Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans.
J. Clin. Microbiol.
35:1473-1476[Abstract].
|
| 15.
|
Werner, E.,
M. Seibold, and E. Antweiler.
1993.
Susceptibility testing of Candida species for fluconazole: the role of buffering in the agar dilution assay.
Mycoses
36:125-130[Medline].
|
| 16.
|
White, T. C.,
K. A. Marr, and R. A. Bowden.
1998.
Clinical, cellular and molecular factors that contribute to antifungal drug resistance.
Clin. Microbiol. Rev.
11:382-402[Abstract/Free Full Text].
|
| 17.
|
Yamada, H.,
T. Watanabe,
K. Kato, and H. Mochizuki.
1997.
Fungicidal mechanism of action of D0870 against Cryptococcus neoformans under acidic conditions.
Antimicrob. Agents Chemother.
41:2710-2713[Abstract].
|
Antimicrobial Agents and Chemotherapy, June 1999, p. 1383-1386, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.